AbbVie’s Rinvoq Achieves Second Phase 3 Win in Alopecia Areata Trials

AbbVie's JAK inhibitor Rinvoq (upadacitinib) met primary endpoints in its second Phase 3 trial for alopecia areata, demonstrating significant hair regrowth123.

In Study 1, 45.2% (15mg) and 55% (30mg) of patients reached 80% scalp hair coverage after 24 weeks; up to 45.8% (30mg) achieved more than 90% coverage, with some patients obtaining full scalp hair coverage1.

Results from Study 2 showed 44.6% (15mg) and 54.3% (30mg) of participants reached at least 80% scalp hair coverage after 24 weeks, compared to minimal gains in the placebo group235.

Key secondary endpoints included improvements in eyebrow and eyelash regrowth; both doses met these targets123.

The safety profile for Rinvoq in alopecia areata aligns with its approved uses:
discontinuation rates due to adverse events were low (1.1% and 1.5% for 15mg and 30mg, respectively), and no new safety signals were observed12.

These results position Rinvoq as a promising new treatment for severe alopecia areata, addressing a substantial unmet need for patients experiencing unpredictable and psychologically impactful hair loss5.

Sources:

1. https://www.clinicaltrialsarena.com/news/abbvie-rinvoq-alopecia-areata-phase-iii/

2. https://www.prnewswire.com/news-releases/abbvie-announces-positive-topline-results-from-phase-3-up-aa-trial-evaluating-upadacitinib-rinvoq-for-alopecia-areata-302517362.html

3. https://pmlive.com/pharma_news/abbvie-shares-promising-phase-3-results-for-rinvoq-in-severe-alopecia-areata/

5. https://www.pharmanow.live/latest-news/abbvie-rinvoq-phase3-alopecia-areata-results